TrialClinical cancer research : an official journal of the American Association for Cancer Research2012

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

D Neil Hayes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.